Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.

Surgical oncology - 1 Sept 2016

Ronnekleiv-Kelly Sean M, Burkhart Richard A, Pawlik Timothy M

Abstract excerpt

Metastatic disease ultimately occurs in approximately 50-70% of patients presenting with colorectal cancer. In patients with advanced disease, there is significant variability in individual patient outcomes. To improve understanding of tumor behavior, markers such as KRAS and BRAF mutation status are increasingly utilized. Additionally, newer surrogates of tumor biology, such as telomerase activity and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Colorectal Neoplasms
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Protein Kinases

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27566022
DOI: 10.1016/j.suronc.2016.05.018
PMCID: PMC5152574

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.PMID 27566022Read ↗

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.Semantic proximity Read ↗

Current and Emerging Biomarkers in Metastatic Colorectal CancerSemantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies.Semantic proximity Read ↗

Molecular Profiling in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.Semantic proximity Read ↗

Prognostic and predictive molecular biomarkers in advanced colorectal cancer.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable MutationSemantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted TherapySemantic proximity Read ↗

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Semantic proximity Read ↗

Biomarker in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.